Expert committee recommends new Novo Nordisk growth hormone for EU approval

Novo Nordisk has broken ground for marketing growth hormone somapacitan in the EU after EMA expert panel CHMP adopts positive opinion of the treatment.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

Just under five months after Novo Nordisk secured a US Food and Drug Administration (FDA) approval for sending the once-weekly growth hormone Sogroya on the market the European Medicines Agency (EMA) also announces their positive assessment of the treatment.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading